BioCentury | Sep 5, 2016
Finance

Medivation elation

...our portfolio at multiple time points. It's one of our top biggest wins." Bain (formerly Brookside Capital...
BioCentury | Jul 11, 2016
Finance

Ground up

...there's zero connection between biotech and what happens to Britain in terms of fundamentals," said Brookside Capital's...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...inherited retinal dystrophies. Muijrers is not the only investor who tapped Spark. Gordon, Thomson and Brookside Capital's...
BioCentury | May 9, 2016
Finance

A clot to consider

...talked to don't think that Biogen is spinning out its fastest-growing source of revenue," said Brookside Capital's...
BioCentury | May 3, 2016
Company News

Koppel to leave Biogen

...Capital as a managing director. He was a managing director at Bain's public equity affiliate, Brookside Capital...
BioCentury | Apr 4, 2016
Finance

Ample opportunity

..."There's an extraordinary amount of interest in the first-line lung data," said Ted Pappendick of Brookside Capital...
BioCentury | Jan 11, 2016
Finance

Sowing season

...platform technologies, but I think are stories that could really appeal in 2016," Pinniger said. 
Brookside Capital's...
BioCentury | Nov 2, 2015
Finance

Flight to liquidity

...compromise on valuation as long as they get substantial positions." According to Dewey Awad at Brookside Capital...
BioCentury | Oct 12, 2015
Finance

ONCE upon a time

..."Stock movements don't reflect quality or the impact of the data every single time," added Brookside Capital's...
BioCentury | Jul 27, 2015
Financial News

RaNATherapeutics completes venture financing

...Raised: $55 million Investors: Merck Research Labs Venture Fund; The Baupost Group; Rock Springs Capital; Brookside Capital...
Items per page:
1 - 10 of 77
BioCentury | Sep 5, 2016
Finance

Medivation elation

...our portfolio at multiple time points. It's one of our top biggest wins." Bain (formerly Brookside Capital...
BioCentury | Jul 11, 2016
Finance

Ground up

...there's zero connection between biotech and what happens to Britain in terms of fundamentals," said Brookside Capital's...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...inherited retinal dystrophies. Muijrers is not the only investor who tapped Spark. Gordon, Thomson and Brookside Capital's...
BioCentury | May 9, 2016
Finance

A clot to consider

...talked to don't think that Biogen is spinning out its fastest-growing source of revenue," said Brookside Capital's...
BioCentury | May 3, 2016
Company News

Koppel to leave Biogen

...Capital as a managing director. He was a managing director at Bain's public equity affiliate, Brookside Capital...
BioCentury | Apr 4, 2016
Finance

Ample opportunity

..."There's an extraordinary amount of interest in the first-line lung data," said Ted Pappendick of Brookside Capital...
BioCentury | Jan 11, 2016
Finance

Sowing season

...platform technologies, but I think are stories that could really appeal in 2016," Pinniger said. 
Brookside Capital's...
BioCentury | Nov 2, 2015
Finance

Flight to liquidity

...compromise on valuation as long as they get substantial positions." According to Dewey Awad at Brookside Capital...
BioCentury | Oct 12, 2015
Finance

ONCE upon a time

..."Stock movements don't reflect quality or the impact of the data every single time," added Brookside Capital's...
BioCentury | Jul 27, 2015
Financial News

RaNATherapeutics completes venture financing

...Raised: $55 million Investors: Merck Research Labs Venture Fund; The Baupost Group; Rock Springs Capital; Brookside Capital...
Items per page:
1 - 10 of 77